What Researchers Did
Researchers reviewed clinical trials investigating strategies to overcome accelerated repopulation and tumor hypoxia in locally advanced head and neck squamous cell carcinoma treated with radiotherapy.
What They Found
Accelerated fractionation regimens delivering the full conventional dose with modest acceleration (e.g., concomitant boost or 6 days/week treatment) showed the best results against accelerated repopulation. The role of accelerated fractionation with chemoradiation is not established, but new approaches like PET imaging and ARCON offer renewed optimism for overcoming tumor hypoxia.
What This Means for Canadian Patients
Canadian patients with locally advanced head and neck squamous cell carcinoma may benefit from specific accelerated radiotherapy schedules designed to counter accelerated repopulation. Emerging strategies to address tumor hypoxia, including advanced imaging and novel therapies, hold promise for improving treatment effectiveness for these patients.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
A limitation is that the review highlighted the unestablished role of accelerated fractionation when combined with chemoradiation, indicating a gap in the evidence base at the time.